GH Research PLC (GHRS)

NASDAQ: GHRS · Real-Time Price · USD
8.61
-0.01 (-0.12%)
Nov 8, 2024, 4:00 PM EST - Market closed
-0.12%
Market Cap 447.96M
Revenue (ttm) n/a
Net Income (ttm) -34.97M
Shares Out 52.03M
EPS (ttm) -0.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 41,589
Open 8.56
Previous Close 8.62
Day's Range 8.41 - 8.89
52-Week Range 5.05 - 14.99
Beta 0.74
Analysts Strong Buy
Price Target 36.67 (+325.9%)
Earnings Date Nov 19, 2024

About GHRS

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company’s lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bip... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 25, 2021
Employees 49
Stock Exchange NASDAQ
Ticker Symbol GHRS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for GHRS stock is "Strong Buy." The 12-month stock price forecast is $36.67, which is an increase of 325.90% from the latest price.

Price Target
$36.67
(325.90% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates

DUBLIN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders,...

2 months ago - GlobeNewsWire

GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer

DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological d...

2 months ago - GlobeNewsWire

GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates

DUBLIN, Ireland, May 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological dis...

6 months ago - GlobeNewsWire

GH Research Reports Full Year 2023 Financial Results and Provides Business Updates

DUBLIN, Ireland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological di...

9 months ago - GlobeNewsWire

GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression

DUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological di...

10 months ago - GlobeNewsWire

GH Research Reports Third Quarter Financial Results and Provides Business Updates

DUBLIN, Ireland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological di...

1 year ago - GlobeNewsWire

GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression

DUBLIN, Ireland, Sept. 29, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological d...

1 year ago - GlobeNewsWire

GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological di...

1 year ago - GlobeNewsWire

GH Research: But Toad Venom Is A Controlled Substance

GH Research PLC is developing mebufotenin, developed from toad venom, as an antidepressant. They have some early positive data. However, toad venom is a controlled substance and will face approval dif...

1 year ago - Seeking Alpha

GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights

DUBLIN, Ireland, May 11, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological dis...

1 year ago - GlobeNewsWire

GH Research Reports Full Year 2022 Financial Results and Provides Business Updates

DUBLIN, Ireland, March 02, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological d...

1 year ago - GlobeNewsWire

Psychedelic Sunday: Competitive Strategies

Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Will first-movers get the advantage?

Other symbols: ATAICMPSCYBNMNMD
1 year ago - Seeking Alpha

GH Research Provides Business Updates and Highlights Key Upcoming Milestones

DUBLIN, Ireland, Jan. 09, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological di...

1 year ago - GlobeNewsWire

GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates

DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological di...

2 years ago - GlobeNewsWire

GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates

DUBLIN, Ireland, Aug. 23, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological di...

2 years ago - GlobeNewsWire

GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates

DUBLIN, Ireland, May 18, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological dis...

2 years ago - GlobeNewsWire

GH Research Reports Full Year 2021 Financial Results and Provides Business Updates

DUBLIN, Ireland., March 28, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological ...

2 years ago - GlobeNewsWire

Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today

Revive Therapeutics (OTC:RVVTF) shares closed up 14.94% at $0.25 ATAI Life Sciences (NASDAQ:ATAI) shares closed up 3.53% at $5.58

3 years ago - Benzinga

GH Research Announces Positive Trial Results For Treatment-Resistant Depression

Clinical-stage biopharmaceutical company GH Research PLC (NASDAQ: GHRS) announced positive results from recent clinical trials of its leading 5-MeO-DMT formula, a therapy candidate for patients suffer...

3 years ago - Benzinga

GH Research Posts Data From Treatment-Resistant Depression Trial

GH Research PLC (NASDAQ: GHRS) has reported the outcome of the Phase 2 part of a Phase 1/2 trial of GH001, an inhalable 5-MeO-DMT product candidate for treatment-resistant depression (TRD). The trial ...

3 years ago - Benzinga

GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates

DUBLIN, Ireland, Dec. 06, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological di...

3 years ago - GlobeNewsWire

GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results

DUBLIN, Ireland, Sept. 23, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological d...

3 years ago - GlobeNewsWire

GH Research: A Recent IPO Stock That Could Possibly Be A Trailblazer In A Hot Industry

The WHO predicts that depression will be the biggest problem in the world during the next decade and beyond. GH Research had a rather successful IPO on the 24th of June.

3 years ago - Seeking Alpha

7 Companies Go Public Today. What Investors Need to Know.

Acurx Pharmaceuticals, Alpha Teknova, Elevation Oncology, GH Research, Graphite Bio, and MissFresh are listed on the Nasdaq. Mister Car Wash is trading the New York Stock Exchange.

Other symbols: ELEVMCWTKNOACXP
3 years ago - Barrons

GH Research Seeks $125 Million IPO

GH Research has filed proposed terms for a $125 million U.S. IPO. The firm is developing treatments for treatment resistant depression and other neurological conditions.

3 years ago - Seeking Alpha